EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Clinical outcomes of a real‐world prospective study using Dexcom ONE continuous glucose monitoring in people with diabetes treated with two or more insulin injections per day

Jackie Elliott, Chloe Husband, Heydar Khadem, Hoda Nemat, Lucy Cardno, Laura Currin, Susan Hudson

Diabetic Medicine · 2025

DOI: 10.1111/dme.15519 ↗

At a glance

Journal article in Diabetic Medicine, 2025. Written by Jackie Elliott and 6 co-authors. Institution: Diabetes and Endocrine Centre, Sheffield Teaching Hospitals, Sheffield, UK. Major MEDLINE topics: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Insulin, Hypoglycemic Agents. Cited 2 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Dexcom, Inc., Dexcom.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

This study assessed real‐world glycaemic outcomes associated with the use of Dexcom ONE in adults with suboptimally controlled diabetes.

Methods

In this single‐site prospective study, adults with type 1 (T1D) or type 2 diabetes (T2D) taking two or more insulin injections per day initiated Dexcom ONE CGM use and attended follow‐up data collection visits after 3 and 6 months. During the study, participants received usual diabetes care. Primary outcome was a change in HbA1c at 6 months. Additional outcomes included change in participant‐reported outcomes and CGM‐derived time in glucose range 3.9–10 mmol/L (TIR), time above range >10 mmol/L (TAR), and time below range

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1InsulinHypoglycemic AgentsBlood Glucose Self-MonitoringBlood GlucoseHumansFemaleMaleMiddle AgedProspective StudiesAdultGlycated HemoglobinTreatment OutcomeGlycemic ControlContinuous Glucose Monitoring

Author keywords

continuous glucose monitoringdeprivationdiabetes distressglycaemic controlglycated haemoglobin

Substances

InsulinHypoglycemic AgentsGlycated HemoglobinBlood Glucosehemoglobin A1c protein, human

Authors and institutions

  • Diabetes and Endocrine Centre, Sheffield Teaching Hospitals, Sheffield, UK.
  • Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
  • Department of Electronic and Electrical Engineering, University of Sheffield, Sheffield, UK.

Funding

  • Dexcom, Inc.
  • Dexcom

Cite

APA

Elliott, J., Husband, C., Khadem, H., Nemat, H., Cardno, L., Currin, L., & Hudson, S. (2025). Clinical outcomes of a real‐world prospective study using Dexcom ONE continuous glucose monitoring in people with diabetes treated with two or more insulin injections per day. Diabetic Medicine. https://doi.org/10.1111/dme.15519

Vancouver

Elliott J, Husband C, Khadem H, Nemat H, Cardno L, Currin L, et al. Clinical outcomes of a real‐world prospective study using Dexcom ONE continuous glucose monitoring in people with diabetes treated with two or more insulin injections per day. Diabetic Medicine. 2025. doi:10.1111/dme.15519

BibTeX
@article{Elliott2025,
  author = {Elliott, Jackie and Husband, Chloe and Khadem, Heydar and Nemat, Hoda and Cardno, Lucy and Currin, Laura and Hudson, Susan},
  title = {Clinical outcomes of a real‐world prospective study using Dexcom ONE continuous glucose monitoring in people with diabetes treated with two or more insulin injections per day},
  journal = {Diabetic Medicine},
  year = {2025},
  doi = {10.1111/dme.15519}
}
Start for free →